About Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s is a combination therapy designed to improve glycemic control in adults with type 2 diabetes mellitus. Sitagliptin works by inhibiting the DPP-4 enzyme, thereby increasing incretin levels, which help regulate insulin and glucagon. Metformin complements this action by reducing glucose production in the liver and improving insulin sensitivity in muscle tissue. Together, these mechanisms support better blood sugar management and reduce the risk of diabetes-related complications. This fixed-dose combination is typically prescribed when monotherapy is insufficient or when patients are already stabilized on separate doses of sitagliptin and metformin.

Indications of Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is especially beneficial for patients who are inadequately controlled on metformin alone or already receiving sitagliptin and metformin separately.

Dosage and Administration of Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

The usual recommended dose is one tablet taken twice daily with meals to minimize gastrointestinal side effects. The dosage should be individualized based on the patient’s current regimen, renal function, and therapeutic goals. Maximum dose should not exceed 100 mg of sitagliptin and 2000 mg of metformin per day. Renal function should be assessed prior to initiation and periodically thereafter.

Contraindications of Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s is contraindicated in patients with:

• Severe renal impairment (eGFR <30 mL/min/1.73 m²)

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

• Known hypersensitivity to sitagliptin, metformin, or any of the tablet’s components

Side Effects of Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

Common side effects include nausea, vomiting, diarrhea, abdominal pain, headache, and respiratory infections. In rare cases, patients may experience serious conditions such as:

• Lactic acidosis (a potentially fatal complication of metformin accumulation)

• Pancreatitis

• Severe allergic reactions like angioedema, urticaria, or anaphylaxis

Precautions for Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

Use with caution in patients with impaired renal function and the elderly. Monitor renal function regularly. Avoid alcohol due to the increased risk of lactic acidosis. Discontinue temporarily prior to imaging procedures using iodinated contrast agents and during surgical procedures requiring restricted food or fluid intake.

Storage of Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s

Store Sitagliptin + Metformin HCI (PHILSITZ-M) 50mg/500mg Tablet 30’s at 15°C to 30°C. Protect from light and moisture. Keep in original packaging and out of reach of children.